Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Zhejiang Ausun Pharmaceutical Co. Ltd. holds a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 1 pending office action. This action is assigned to 1 distinct examiner and 1 distinct art unit. CORNET, JEAN P is the busiest examiner, with 1 pending office action. The prosecution of this portfolio is currently very focused, with only 1 pending office action being reviewed by 1 distinct examiner.
The involvement of 1 distinct art unit indicates that the Biotechnology & Pharmaceuticals technology is being evaluated within a specific group. Practitioners should focus on the specific requirements of CORNET, JEAN P to resolve the 1 pending office action. The examiner's individual interpretation of the 1 pending office action will be the primary factor in the company's patenting progress. Practitioners should focus on the specific requirements of the 1 distinct art unit to move the case forward. This focused approach allows for a dedicated response to the examiner's specific concerns regarding the 1 pending office action.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CORNET, JEAN P | 1 | 42.1% | +47.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18034144 | APPLICATION OF BZP IN TREATMENT OF ISCHEMIC CARDIOVASCULAR AND CEREBRAL VASCULAR DISEASES | CORNET, JEAN P | 25d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18034144 | APPLICATION OF BZP IN TREATMENT OF ISCHEMIC CARDIOVASCULAR AND CEREBRAL VASCULAR DISEASES | CORNET, JEAN P | 25d overdue |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18034144 | APPLICATION OF BZP IN TREATMENT OF ISCHEMIC CARDIOVASCULAR AND CEREBRAL VASCULAR DISEASES | CORNET, JEAN P | 1628 | §103§112 | Final Rejection | 25d overdue | Pending | Apr 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial